Grant: CIHR-ICRH Travel Awards - ICRH / Vascular pool

Transthyretin amyloidosis cardiomyopathy is a disease that affects the heart tissue caused by the accumulation of abnormal proteins called amyloid plaques. Despite the approval of tafamidis, a stabilizer therapy, significant knowledge gaps exist regarding its use due to strict eligibility criteria and high costs. This study identified parameters that could be used in the predicting adverse outcomes of all-cause and cardiovascular mortality and hospitalization, as well as the associations of these predictors to tafamidis therapy. Various measures of baseline function were found to be associated with outcome and therapy.